Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion

1. Novo Nordisk to acquire Akero for $54 per share in cash. 2. Shareholders may receive an extra $6 per share pending U.S. regulatory approval. 3. Akero's EFX shows promise for treating metabolic diseases and cirrhosis. 4. AKRO stock surged 17.64% following the acquisition announcement. 5. Novo Nordisk's cash flow may dip due to the acquisition's financing.